{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:31:38Z","timestamp":1773801098561,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016112","name":"Universit\u00e0 di Foggia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016112","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      People with Cystic Fibrosis (pwCF) are prone to bacterial lung infections with\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      , which have been linked to chronic inflammation in the lung. Although the highly effective CFTR modulator therapy (Elexacaftor-Tezacaftor-Ivacaftor, ETI) has dramatically improved respiratory outcomes in pwCF, airway inflammation and bacterial colonization persist in the upper and lower respiratory tracts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We investigated the effect of ETI in both plasma and fresh primary nasal epithelial (HNE) cells obtained from pwCF pre- and post-three months of ETI treatment. Given that inflammation has been shown to upregulate NFKBIZ and the ATP12A proton pump, we measured their levels in fresh HNE cells and in cultured HNE cells exposed to clinical exoproducts (EXO) of\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      or other inflammatory stimuli.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ELISA analysis revealed a significant reduction of IL-6, IL-8, and IL-17C in both plasma and HNE cells after ETI treatment. NFKBIZ and ATP12A expression was increased after infection and inflammatory stimuli in CF bronchial epithelial (CFBE) and HNE cells, and this increase was reduced by Dimethyl-Fumarate, an anti-inflammatory drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These preclinical studies, using patient-derived tissues, suggest that NFKBIZ and ATP12A may play a relevant role in the pathophysiology and inflammatory response of the CF airway epithelium.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00011-026-02210-z","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:18:44Z","timestamp":1773746324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of ATP12A and NFKBIZ as potential markers of inflammatory status in cystic fibrosis airway epithelial cells"],"prefix":"10.1007","volume":"75","author":[{"given":"Caterina","family":"Allegretta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Guidone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Fevola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Ciciriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enza","family":"Montemitro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Dolce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Cabrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis J. V.","family":"Galietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onofrio","family":"Laselva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"2210_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081321","author":"IAL Silva","year":"2022","unstructured":"Silva IAL, Laselva O, Lopes-Pacheco M. Advances in preclinical in vitro models for the translation of precision medicine for cystic fibrosis. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12081321.","journal-title":"J Pers Med"},{"issue":"17","key":"2210_CR2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, et al. VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612\u201320.","journal-title":"N Engl J Med"},{"issue":"19","key":"2210_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"8","key":"2210_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","volume":"78","author":"M Casey","year":"2023","unstructured":"Casey M, et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 2023;78(8):835\u20139.","journal-title":"Thorax"},{"issue":"6","key":"2210_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17476348.2016.1177460","volume":"10","author":"H Lund-Palau","year":"2016","unstructured":"Lund-Palau H, et al. Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Rev Respir Med. 2016;10(6):685\u201397.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"2210_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1385\/CRIAI:23:1:005","volume":"23","author":"JF Chmiel","year":"2002","unstructured":"Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol. 2002;23(1):5\u201327.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"2210_CR7","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1183\/09031936.00076214","volume":"45","author":"NT Trinh","year":"2015","unstructured":"Trinh NT, et al. Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells. Eur Respir J. 2015;45(6):1590\u2013602.","journal-title":"Eur Respir J"},{"issue":"5","key":"2210_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127742","volume":"10","author":"BA Stanton","year":"2015","unstructured":"Stanton BA, et al. Pseudomonas aeruginosa reduces VX-809 stimulated F508del-CFTR chloride secretion by airway epithelial cells. PLoS ONE. 2015;10(5):e0127742.","journal-title":"PLoS ONE"},{"key":"2210_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00970-2024","author":"C Allegretta","year":"2025","unstructured":"Allegretta C, et al. Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor\/tezacaftor\/ivacaftor is clinical strain-dependent in patient-derived nasal cells. ERJ Open Res. 2025. https:\/\/doi.org\/10.1183\/23120541.00970-2024.","journal-title":"ERJ Open Res"},{"key":"2210_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020334","author":"O Laselva","year":"2020","unstructured":"Laselva O, et al. Anti-infectives restore ORKAMBI((R)) rescue of F508del-CFTR function in human bronchial epithelial cells infected with clinical strains of P. aeruginosa. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10020334.","journal-title":"Biomolecules"},{"issue":"7405","key":"2210_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature11130","volume":"487","author":"AA Pezzulo","year":"2012","unstructured":"Pezzulo AA, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012;487(7405):109\u201313.","journal-title":"Nature"},{"issue":"6272","key":"2210_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.aad5589","volume":"351","author":"VS Shah","year":"2016","unstructured":"Shah VS, et al. Airway acidification initiates host defense abnormalities in cystic fibrosis mice. Science. 2016;351(6272):503\u20137.","journal-title":"Science"},{"key":"2210_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123616","author":"P Scudieri","year":"2018","unstructured":"Scudieri P, et al. Increased expression of ATP12A proton pump in cystic fibrosis airways. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.123616.","journal-title":"JCI Insight"},{"issue":"2S","key":"2210_CR14","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.jcf.2017.10.006","volume":"17","author":"SL Martin","year":"2018","unstructured":"Martin SL, et al. Ion channels as targets to treat cystic fibrosis lung disease. J Cyst Fibros. 2018;17(2S):S22\u20137.","journal-title":"J Cyst Fibros"},{"issue":"22","key":"2210_CR15","doi-asserted-by":"publisher","first-page":"e164944","DOI":"10.1172\/jci.insight.164944","volume":"7","author":"D Guidone","year":"2022","unstructured":"Guidone D, et al. Airway surface hyperviscosity and defective mucociliary transport by IL-17\/TNF-alpha are corrected by beta-adrenergic stimulus. JCI Insight. 2022;7(22):e164944.","journal-title":"JCI Insight"},{"issue":"3","key":"2210_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1165\/rcmb.2014-0370OC","volume":"53","author":"K Sundaram","year":"2015","unstructured":"Sundaram K, et al. House dust mite allergens and the induction of monocyte interleukin 1beta production that triggers an IkappaBzeta-dependent granulocyte macrophage colony-stimulating factor release from human lung epithelial cells. Am J Respir Cell Mol Biol. 2015;53(3):400\u201311.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2210_CR17","doi-asserted-by":"publisher","first-page":"1188253","DOI":"10.3389\/fimmu.2023.1188253","volume":"14","author":"Y Feng","year":"2023","unstructured":"Feng Y, et al. The central inflammatory regulator IkappaBzeta: induction, regulation and physiological functions. Front Immunol. 2023;14:1188253.","journal-title":"Front Immunol"},{"issue":"5","key":"2210_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/immunohorizons.1900023","volume":"3","author":"R Muromoto","year":"2019","unstructured":"Muromoto R, et al. IkappaB-zeta expression requires both TYK2\/STAT3 activity and IL-17-regulated mRNA stabilization. Immunohorizons. 2019;3(5):172\u201385.","journal-title":"Immunohorizons"},{"issue":"4","key":"2210_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1277","volume":"10","author":"F Xiao","year":"2021","unstructured":"Xiao F, et al. IL-17 drives salivary gland dysfunction via inhibiting TRPC1-mediated calcium movement in Sjogren\u2019s syndrome. Clin Transl Immunol. 2021;10(4):e1277.","journal-title":"Clin Transl Immunol"},{"issue":"9","key":"2210_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","volume":"180","author":"PA Flume","year":"2009","unstructured":"Flume PA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2210_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153\u201378.","journal-title":"J Cyst Fibros"},{"key":"2210_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092090","author":"P Scudieri","year":"2020","unstructured":"Scudieri P, et al. Ionocytes and CFTR chloride channel expression in normal and cystic fibrosis nasal and bronchial epithelial cells. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9092090.","journal-title":"Cells"},{"issue":"2","key":"2210_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/jpm10020040","volume":"10","author":"O Laselva","year":"2020","unstructured":"Laselva O, et al. The CFTR Mutation c.3453G > C (D1152H) Confers an anion selectivity defect in primary airway tissue that can be rescued by ivacaftor. J Pers Med. 2020;10(2):40.","journal-title":"J Pers Med"},{"issue":"1","key":"2210_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jcf.2020.07.015","volume":"20","author":"O Laselva","year":"2021","unstructured":"Laselva O, et al. Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants. J Cyst Fibros. 2021;20(1):106\u201319.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2210_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10571-024-01494-1","volume":"44","author":"M Di Chiano","year":"2024","unstructured":"Di Chiano M, et al. Lactobacilli cell-free supernatants modulate inflammation and oxidative stress in human microglia via NRF2-SOD1 signaling. Cell Mol Neurobiol. 2024;44(1):60.","journal-title":"Cell Mol Neurobiol"},{"key":"2210_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082132","author":"O Laselva","year":"2021","unstructured":"Laselva O, et al. Anti-inflammatory and anti-oxidant effect of dimethyl fumarate in cystic fibrosis bronchial epithelial cells. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10082132.","journal-title":"Cells"},{"key":"2210_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.905468","volume":"9","author":"O Laselva","year":"2022","unstructured":"Laselva O, et al. Insulin-like growth factor binding protein (IGFBP-6) as a novel regulator of inflammatory response in cystic fibrosis airway cells. Front Mol Biosci. 2022;9:905468.","journal-title":"Front Mol Biosci"},{"key":"2210_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2025.104926","volume":"409\u2013410","author":"C Allegretta","year":"2025","unstructured":"Allegretta C, et al. IL-17 family members exert an autocrine pro-inflammatory loop in CF respiratory epithelial cells ex vivo. Cell Immunol. 2025;409\u2013410:104926.","journal-title":"Cell Immunol"},{"key":"2210_CR29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022","author":"L Schaupp","year":"2023","unstructured":"Schaupp L, et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J. 2023. https:\/\/doi.org\/10.1183\/13993003.02153-2022.","journal-title":"Eur Respir J"},{"issue":"7","key":"2210_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","volume":"205","author":"C Gabillard-Lefort","year":"2022","unstructured":"Gabillard-Lefort C, et al. Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis. Am J Respir Crit Care Med. 2022;205(7):783\u201394.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"2210_CR31","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","volume":"209","author":"J Loske","year":"2024","unstructured":"Loske J, et al. Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis. Am J Respir Crit Care Med. 2024;209(11):1338\u201350.","journal-title":"Am J Respir Crit Care Med"},{"key":"2210_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-222242","author":"RE Maher","year":"2025","unstructured":"Maher RE, et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on systemic inflammation in cystic fibrosis. Thorax. 2025. https:\/\/doi.org\/10.1136\/thorax-2024-222242.","journal-title":"Thorax"},{"key":"2210_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167957","author":"DP Nichols","year":"2023","unstructured":"Nichols DP, et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI167957.","journal-title":"J Clin Invest"},{"issue":"2","key":"2210_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1742-4658.2011.08416.x","volume":"279","author":"T Ohba","year":"2012","unstructured":"Ohba T, et al. Identification of interleukin-1 receptor-associated kinase 1 as a critical component that induces post-transcriptional activation of IkappaB-zeta. FEBS J. 2012;279(2):211\u201322.","journal-title":"FEBS J"},{"issue":"3","key":"2210_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.bbrc.2015.12.068","volume":"469","author":"T MaruYama","year":"2016","unstructured":"MaruYama T, et al. Screening of posttranscriptional regulatory molecules of IkappaB-zeta. Biochem Biophys Res Commun. 2016;469(3):711\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2210_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, et al. Future therapies for cystic fibrosis. Nat Commun. 2023;14(1):693.","journal-title":"Nat Commun"},{"key":"2210_CR37","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0001-2024","author":"MA Mall","year":"2024","unstructured":"Mall MA, et al. Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target. Eur Respir Rev. 2024. https:\/\/doi.org\/10.1183\/16000617.0001-2024.","journal-title":"Eur Respir Rev"},{"issue":"14","key":"2210_CR38","doi-asserted-by":"publisher","first-page":"e181836","DOI":"10.1172\/jci.insight.181836","volume":"9","author":"T Rehman","year":"2024","unstructured":"Rehman T, et al. Epithelial responses to CFTR modulators are improved by inflammatory cytokines and impaired by antiinflammatory drugs. JCI Insight. 2024;9(14):e181836.","journal-title":"JCI Insight"},{"issue":"2","key":"2210_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jcf.2013.10.007","volume":"13","author":"G Doring","year":"2014","unstructured":"Doring G, et al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros. 2014;13(2):156\u201363.","journal-title":"J Cyst Fibros"},{"key":"2210_CR40","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3389\/fimmu.2020.01438","volume":"11","author":"G Cabrini","year":"2020","unstructured":"Cabrini G, et al. Role of cystic fibrosis bronchial epithelium in neutrophil chemotaxis. Front Immunol. 2020;11:1438.","journal-title":"Front Immunol"},{"key":"2210_CR41","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00502-2024","author":"S Bani Melhim","year":"2024","unstructured":"Bani Melhim S, et al. The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis. ERJ Open Res. 2024. https:\/\/doi.org\/10.1183\/23120541.00502-2024.","journal-title":"ERJ Open Res"},{"key":"2210_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.freeradbiomed.2025.06.022","volume":"237","author":"L Liu","year":"2025","unstructured":"Liu L, et al. Hepatic IkappaBzeta promotes alcohol-associated liver disease and acute hepatitis by enhancing CXCL1-mediated neutrophil infiltration. Free Radic Biol Med. 2025;237:558\u201369.","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"2210_CR43","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1073\/pnas.1912702117","volume":"117","author":"K Slowikowski","year":"2020","unstructured":"Slowikowski K, et al. CUX1 and IkappaBzeta (NFKBIZ) mediate the synergistic inflammatory response to TNF and IL-17A in stromal fibroblasts. Proc Natl Acad Sci U S A. 2020;117(10):5532\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2210_CR44","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.4049\/jimmunol.168.9.4781","volume":"168","author":"R Loewe","year":"2002","unstructured":"Loewe R, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B\/p65 in human endothelial cells. J Immunol. 2002;168(9):4781\u20137.","journal-title":"J Immunol"},{"issue":"2","key":"2210_CR45","doi-asserted-by":"publisher","first-page":"L326","DOI":"10.1152\/ajplung.90624.2008","volume":"297","author":"P Seidel","year":"2009","unstructured":"Seidel P, et al. Dimethylfumarate inhibits NF-kappaB function at multiple levels to limit airway smooth muscle cell cytokine secretion. Am J Physiol Lung Cell Mol Physiol. 2009;297(2):L326\u201339.","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02210-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02210-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02210-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:02:27Z","timestamp":1773788547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02210-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2210"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02210-z","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"51"}}